MedPath

Docetaxel in Treating Patients With Non-Small Cell Lung Cancer

Phase 3
Conditions
Lung Cancer
Registration Number
NCT00022022
Lead Sponsor
Istituto Nazionale per lo Studio e la Cura dei Tumori
Brief Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which chemotherapy regimen is more effective in treating non-small cell lung cancer.

PURPOSE: Randomized phase III trial to compare two different docetaxel regimens in treating patients who have stage IIIB or stage IV non-small cell lung cancer.

Detailed Description

OBJECTIVES:

* Compare the quality of life of patients with stage IIIB or IV non-small cell lung cancer treated with 2 different schedules of docetaxel as second-line therapy.

* Compare the toxicity of these regimens in these patients.

* Compare the response rate, time to progression, and survival of these patients treated with these regimens.

OUTLINE: This is a randomized, multicenter study. Patients are stratified according to center, ECOG performance status (0 vs 1 vs 2), response to prior chemotherapy (partial or complete response vs stable disease vs progressive disease), and prior cisplatin-containing chemotherapy regimen (yes vs no). Patients are randomized to 1 of 2 treatment arms.

* Arm I: Patients receive docetaxel IV on day 1. Treatment continues every 3 weeks for a maximum of 6 courses.

* Arm II: Patients receive docetaxel IV weekly for 6 weeks. Treatment continues every 8 weeks for a maximum of 2 courses.

Quality of life is assessed at baseline and days 22 and 43-56 for arm I, and at baseline and days 22 and 43 for arm II.

PROJECTED ACCRUAL: A total of 200 patients will be accrued for this study.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
200
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Quality of life
Toxicity
Response rate
Time to progression
Survival
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (16)

Istituto Di Ricovero E Cura A Carattere Scientifico

🇮🇹

Bari, Italy

Ospedale San Paolo

🇮🇹

Milano, Italy

Ospedale Luigi Sacco

🇮🇹

Milan, Italy

Ospedale Vincenzo Monaldi

🇮🇹

Naples, Italy

Istituto Nazionale per lo Studio e la Cura dei Tumori

🇮🇹

Naples, Italy

Azienda Ospedaliena G. Rummo

🇮🇹

Benevento, Italy

Ospedale Civile Cosenza

🇮🇹

Cosenza, Italy

Ospedale San Giuseppe

🇮🇹

Milan, Italy

Federico II University Medical School

🇮🇹

Naples, Italy

Ospedale Civile P.F. Calvi

🇮🇹

Noale, Italy

Azienda Ospedaliera Policlinico Paolo Giaccone

🇮🇹

Palermo, Italy

Ospedale San Carlo

🇮🇹

Potenza, Italy

Ospedale Cardarelli - Campobasso

🇮🇹

Campobasso, Italy

Seconda Universita di Napoli

🇮🇹

Naples, Italy

Ospedale da Procida

🇮🇹

Salerno, Italy

Ospedale La Maddalena - Palermo

🇮🇹

Palermo, Italy

© Copyright 2025. All Rights Reserved by MedPath